✦ LIBER ✦

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

✍ Scribed by Visser, M. E.; Wagener, G.; Baker, B. F.; Geary, R. S.; Donovan, J. M.; Beuers, U. H. W.; Nederveen, A. J.; Verheij, J.; Trip, M. D.; Basart, D. C. G.; Kastelein, J. J. P.; Stroes, E. S. G.

Book ID: 121698130
Publisher: Oxford University Press
Year: 2012
Tongue: English
Weight: 301 KB
Volume: 33
Category: Article
ISSN: 0195-668X
DOI: 10.1093/eurheartj/ehs023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mipomersen, an apolipoprotein B synthesi

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

✍ Frederick J Raal; Raul D Santos; Dirk J Blom; A David Marais; Min-Ji Charng; Wil 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 278 KB

Effectiveness of the addition of ezetimi

Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-controlled trial

✍ Thomas Pearson; Margo Denke; Patrick McBride; Wendy P Battisti; William E. Brady 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 816 KB

Effects of simvastatin on the lipid prof

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial

✍ Andrew J. Lewin; Mark S. Kipnes; Luigi F. Meneghini; Diane J. Plotkin; Inna T. P 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 175 KB